Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: A propensity score matching study

Respiratory Research

Volumn 14, Issue 1, 2013, Pages

  Horita, Nobuyuki ^a,b   Miyazawa, Naoki ^b   Morita, Satoshi ^c   Kojima, Ryota ^b   Kimura, Naoko ^b   Kaneko, Takeshi ^c   Ishigatsubo, Yoshiaki ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b SAISEIKAI YOKOHAMASHI NANBU HOSPITAL   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Bronchodilator agents; Case control study; Propensity score; Treatment outcome

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

AGED; ARTICLE; BLOOD CARBON DIOXIDE TENSION; BLOOD OXYGEN TENSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RESIDUAL VOLUME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; INCIDENCE; JAPAN; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SURVIVAL; SURVIVAL RATE;

ADRENERGIC BETA-AGONISTS; AGED; FEMALE; HUMANS; INCIDENCE; JAPAN; MALE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84878354830     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-14-62     Document Type: Article

References (16)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 2011, http://www.goldcopd.org/.
2. Van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129(3):509-517. 10.1378/chest.129.3.509, 16537846.
3. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789. 10.1056/NEJMoa063070, 17314337.
4. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(5):1087-1092. 10.1164/ajrccm.163.5.9903053, 11316640.
5. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997, 155(4):1283-1289. 10.1164/ajrccm.155.4.9105068, 9105068.
6. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006, 61(2):122-128. 10.1136/thx.2004.033266, 2104567, 16443706.
7. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992, 326(8):501-506. 10.1056/NEJM199202203260801, 1346340.
8. Rationale and design of The National Emphysema Treatment Trial a prospective randomized trial of lung volume reduction surgery. The National Emphysema Treatment Trial Research Group. Chest 1999, 116(6):1750-1761. 10.1378/chest.116.6.1750, 10593802, Rationale and design of The National Emphysema Treatment Trial.
9. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 152(5 Pt 2):S77-S121. American Thoracic Society.
10. Rosenbaum PRRD. Reducing Bias in Observational studies Using Subclassification on the Propensity Score. J Am Stat Assoc 1984, 79(387):516-524.
11. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA 2001, 286(10):1187-1194. 10.1001/jama.286.10.1187, 11559263.
12. Mehta RL, Pascual MT, Soroko S, Chertow GM. PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002, 288(20):2547-2553. 10.1001/jama.288.20.2547, 12444861.
13. La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med 2007, 356(21):2211-2;2213-4.
14. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008, 31(5):927-933. 10.1183/09031936.00098307, 18216056.
15. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006, 21(10):1011-1019. 10.1111/j.1525-1497.2006.00507.x, 1831628, 16970553.
16. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61(10):849-853. 10.1136/thx.2006.059808, 2104755, 16738034.